HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54

Benzinga · 4d ago
HC Wainwright & Co. analyst Douglas Tsao maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $52 to $54.